The application of Oct4 CM, c-Myc CM, and Oct4/c-Myc CM to tumor cells reduced the proliferation, migration, invasion, and growth of three-dimensional tumor spheroids, and in the mouse models, the systemic administration of CMs inhibited the growth of mammary tumors and bone degradation. This evidence concerns the gene POU5F1 and breast cancer.